Literature DB >> 24440300

Urokinase-type plasminogen activator expression and Rac1/WAVE-2/Arp2/3 pathway are blocked by pterostilbene to suppress cell migration and invasion in MDA-MB-231 cells.

Hyun Suk Ko1, Ji Sung Kim1, Sun Mi Cho1, Hyo-Jeong Lee1, Kwang Seok Ahn1, Sung-Hoon Kim1, Eun-Ok Lee2.   

Abstract

Breast cancer is the most common malignancy among females, and cancer invasion and metastasis are the leading causes of cancer death in breast cancer patients. Pterostilbene, a naturally occurring dimethylether analogue of resveratrol, has been demonstrated to possess anti-cancer effects. However, inhibitory effects of pterostilbene on cell migration and invasion and its underlying mechanisms are not fully understood. In this study, we investigated the anti-invasive mechanisms of pterostilbene in human breast cancer cell line MDA-MB-231 cells. Pterostilbene effectively inhibited serum-induced migration and invasion without affecting the viability of breast cancer cells. The mRNA expression and activity of urokinase-type plasminogen activator (uPA) were markedly reduced by pterostilbene treatment. Moreover, pterostilbene attenuated nuclear factor κB (NF-κB) transcriptional activity and DNA binding of NF-κB on uPA promoter. In addition, pterostilbene significantly impaired the activity of Rac1 and the expression of WASP-family verprolin-homologous protein-2 (WAVE-2) and actin-related protein 2/3 (Arp2/3). Overall, these results suggest that pterostilbene caused considerable suppression of cell migration and invasion through blocking NF-κB-mediated uPA expression and Rac1/WAVE/Arp2/3 pathway.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Arp2/3; Invasion; MDA-MB-231 cells; Migration; NF-κB; Pterostilbene; Rac1; WAVE; uPA

Mesh:

Substances:

Year:  2014        PMID: 24440300     DOI: 10.1016/j.bmcl.2013.12.115

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Mangiferin inhibits cell migration and invasion through Rac1/WAVE2 signalling in breast cancer.

Authors:  Qing Deng; Yan-Xiao Tian; JianJun Liang
Journal:  Cytotechnology       Date:  2018-02-17       Impact factor: 2.058

2.  Synthesis and antiproliferative activity of pterostilbene and 3′-methoxy pterostilbene Mannich base derivatives against Hela cells.

Authors:  Chongyang Liu; Linpei Dong; Shengchun Wang; Qiuan Wang
Journal:  Mol Divers       Date:  2015-07-11       Impact factor: 2.943

Review 3.  Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis.

Authors:  Bethan Frugtniet; Wen G Jiang; Tracey A Martin
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-04-24

4.  Rac1/Wave2/Arp3 Pathway Mediates Rat Blood-Brain Barrier Dysfunction under Simulated Microgravity Based on Proteomics Strategy.

Authors:  Ranran Yan; Huayan Liu; Fang Lv; Yulin Deng; Yujuan Li
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

5.  Inhibition of Rac1 GTPase activity affects porcine oocyte maturation and early embryo development.

Authors:  Si-Jing Song; Qiao-Chu Wang; Ru-Xia Jia; Xiang-Shun Cui; Nam-Hyung Kim; Shao-Chen Sun
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

Review 6.  Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer.

Authors:  Rong-Jane Chen; Hsiao-Che Kuo; Li-Hsin Cheng; Yu-Hsuan Lee; Wen-Tsan Chang; Bour-Jr Wang; Ying-Jan Wang; Hung-Chi Cheng
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

Review 7.  [Emerging Actions of Pterostilebene on Cancer Research].

Authors:  Xiaoyan Zhang; Jiao Zhang; Liqun Xu; Zhiqiang Ma; Shouyin Di; Yuan Gao; Xiaofei Li; Xiaolong Yan; Hongmei Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-12-20

Review 8.  Recent Advances in Synthesis, Bioactivity, and Pharmacokinetics of Pterostilbene, an Important Analog of Resveratrol.

Authors:  Yeju Liu; Yuyang You; Juan Lu; Xi Chen; Zhihong Yang
Journal:  Molecules       Date:  2020-11-06       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.